Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38+0.00 (0.00%)
Close on Nov 18, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Inhibikase Therapeutics's revenue for the twelve months ending Sep 30, 2025 was $0, down 100.0% year over year. For fiscal 2024 it was $0, down 100.0% from the year before. The highest annual figure on record is $3.10M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $260.50K | +111.0% |
| FY2022 | Dec 31, 2022 | $123.44K | -96.0% |
| FY2021 | Dec 31, 2021 | $3.10M | +343.9% |
| FY2020 | Dec 31, 2020 | $698.47K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q1 FY2026 | Mar 31, 2026 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $1 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $79.57K | +991.3% |
| Q2 FY2023 | Jun 30, 2023 | $116.41K | +1676.7% |
| Q1 FY2023 | Mar 31, 2023 | $64.52K | +40.2% |
| Q4 FY2022 | Dec 31, 2022 | $63.57K | -95.3% |
| Q3 FY2022 | Sep 30, 2022 | $7.29K | -99.5% |
| Q2 FY2022 | Jun 30, 2022 | $6.55K | -96.2% |
| Q1 FY2022 | Mar 31, 2022 | $46.03K | +22.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.36M | +520.7% |
| Q1 FY2021 | Mar 31, 2021 | $1.41M | +419.7% |
| Q4 FY2020 | Dec 31, 2020 | $170.42K | – |
| Q3 FY2020 | Sep 30, 2020 | $37.68K | – |
| Q2 FY2020 | Jun 30, 2020 | $219.59K | – |
| Q1 FY2020 | Mar 31, 2020 | $270.79K | – |
See a number that looks wrong?